Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease (ATtackMy-ILD)

  • End date
    May 30, 2023
  • participants needed
  • sponsor
    Rohit Aggarwal, MD
Updated on 13 May 2022
immunosuppressive agents
tumor necrosis factor
pulmonary disease
intravenous immunoglobulin
interstitial lung disease


A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.


This is a proof of concept study to evaluate the efficacy, safety and tolerability of abatacept in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Condition Myositis, Interstitial Lung Disease
Treatment Placebo, Abatacept
Clinical Study IdentifierNCT03215927
SponsorRohit Aggarwal, MD
Last Modified on13 May 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Anti-synthetase syndrome defined as the patient possessing 1 antisynthetase autoantibody (Jo-1, PL-12, PL-7, KS, OJ, EJ, Zo) in the presence of autoimmune ILD
ILD defined by radiographic (HRCT chest) findings of reticulation, honeycombing or ground glass opacities (GGO) without another plausible explanation. HRCT chest defining ILD for inclusion criteria, should be within last 1 year done as SOC
Active ILD (see Section 4.2)
Baseline FVC a) % <80% b) FVC 80-100% with > = 10% decline in FVC in last 12 months as minimal threshold of ILD severity (PFT done within last 3 months is acceptable for inclusion criteria determination)
SOC immunosuppressive therapy (IS) therapy
Steroids (prednisone or other forms of steroid in equivalent doses) OR one of the other immunosuppressive agent (either Mycophenolate (MMF) or Azathioprine (AZA) OR a combination of steroid and an immunosuppressive agent. MMF (maximum of 3 gm/day) or azathioprine (maximum of 200 mg/day).Goal is to start the trial drug (or placebo) soon after starting SOC (MMF/AZA/Steroids) and their doses are stable. Note that patients on steroids alone as well as not on steroids can be enrolled in the trial as well
Desired dose of the SOC therapy should be reached 4 weeks prior to first study visit (Visit 1). No dose changes are allowed 4 weeks prior to first study visit
Dose of concomitant therapy (SOC) cannot be changed during the 24 weeks of the trial unless safety/toxicity issues supervene
If on steroid, the steroid dose must be stable for 2 weeks prior to Visit 1
No other concomitant IS medications including methotrexate, cyclosporine, intravenous
No concomitant biologic agents (i.e. rituximab, anti-tumor necrosis factor (TNF) agents, tocilizumab)
immunoglobulin (IVIG), tacrolimus, cyclophosphamide or tofacitinib
Additional IS therapy: Patient cannot begin any new IS therapy or new steroid taper for the 24-week study period, except if severe clinical worsening (flare up) of the disease requiring rescue therapy occurs (i.e. documentation of worsening of PFT/HRCT and patient and physician determination of worsening). See section of rescue medication below for details
If the enrolling physician is planning to discontinue current IS agent or steroid before clinical trial, then following washout period is required prior to Visit 1
Medication Washout Period methotrexate 4 weeks Other IS agent (e.g
azathioprine, cyclosporine, tacrolimus, leflunomide, mycophenolate mofetil) 4
weeks IVIg or cyclophosphamide 3 months rituximab 6 months infliximab or
adalimumab 8 weeks glucocorticoids 2 weeks etanercept 2 weeks anakinra 1 week
pirfenidone 4 weeks
Men and women of reproductive potential must agree to use an acceptable method of birth control during the trial period
Subject has provided written informed consent

Exclusion Criteria

A patient will be excluded if any of the following Exclusion Criteria are met
Severe end stage lung disease
FVC ≤30% or Forced expiratory volume (FEV1) ≤ 30% or
Requirement of high O2 requirement ≥ 6 L/min at rest for >1 month before the study enrollment or
Listed for lung transplantation or
PI feels that ILD is severe and end stage fibrosis is such that there is low potential for improvement with any disease modifying intervention
Subjects under the age of 18
Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds)
Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening
Active tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent TB using purified protein derivative (PPD)/or quantiferon gold within last 1 year and, if positive, treated following local practice guidelines prior to initiating abatacept (ABT). Patients treated for active tuberculosis with no recurrence in 3 years are permitted
Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation
Pregnant women or nursing (breast feeding) mothers
History of alcohol, drug or chemical abuse within 1 year prior to screening or any medical condition or physical or psychological state that the PI feels would not allow the subject to safely complete the study
Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization
Treatment with any other investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
Previous treatment with the following cell-depleting therapies, including investigational agents or approved therapies: CAMPATH, anti-CD4, anti-CD5, and anti-CD3
Previous treatment with ABT
History of severe allergic or anaphylactic reactions to monoclonal antibodies
Evidence of serious uncontrolled concomitant cardiovascular, nervous system, renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, ulcerative colitis, or Crohn's disease.)
Evidence of concomitant lung disease which PI feels may interfere with clinical assessment of ILD for example severe active chronic obstructive pulmonary disease (COPD), asthma, occupational lung disease, pulmonary sarcoidosis, etc
Prisoners or subjects who are compulsory detained
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note